Start Submission Become a Reviewer

Reading: Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary interve...

Download

A- A+
Alt. Display

Research

Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary intervention (PCI) in a tertiary level hospital in Bangladesh

Authors:

Syed Ali Ahsan,

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

Md. Abu Salim ,

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

Ayesha Rafiq,

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

Abu Siddique,

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

S.K. Banerjee,

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

Harisul Haque,

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

Manzoor Mahmood

Department of Cardiology, Bangabandhu Sheikh Mujub Medical University (BSMMU), Shahbagh, Dhaka, BD
X close

Abstract

Objectives: To evaluate the effectiveness of a single bolus dose of eptifibatide in elective percutaneous coronary intervention.

Methods: The outcomes of 85 consecutive patients who underwent elective coronary stenting from January 2007 to December 2007 were assessed prospectively. Forty-four patients received eptifibrate (15 mg single bolus dose) after crossing the lesion and 41 patients did not receive eptifibatide. All patients were treated with aspirin and clopidogrel before and after the procedure and all received a single bolus dose of clopidogrel (300 mg) before the procedure. All patients received weight-adjusted doses of heparin before and after the procedure. The primary endpoint for the study was the 30-day incidence of death, myocardial infarction, urgent repeat revascularization or in-hospital major bleeding. Major adverse cardiac events were assessed during hospitalization and one month post-procedure. CK-MB was measured postprocedure in all symptomatic patients.

Results: Mean age of Group I (Eptifibatide used) was 52.34 ± 8.90 years, and Group-II (Eptifibatide not used) was 49.68 ± 8.87 years. In group-I 38.63% had history of Myocardial Infarction (MI), 9.09% had history of Unstable angina (UA), 52.27% had history to chronic stable angina (SA), 54.54% was hypertensive, 40.90% were diabetic, 63.63% had dyslipidemia; 56.81% was diagnoses as single vessel disease (SVD), 36.36% was double vessel disease (DVD). Among group-II patients, 36.58 5 had history of MI, 12.19% had history of UA, 51.21% had history of SA, 51.21% was hypertensive, 26.82% was diabetic, 60.97% had dyslipidemia, 63.41% was diagnosed as a SVD, 29.26% was DVD. In short term (one month) outcome, Group I patients had statistically significant less complications in comparison to Group-II patient (p = 0.017). In Group-I only 2.27% had Q wave MI AND 2.27% had minor bleeding complication, whereas in Group-II patients 9.76% had Q wave MI, 7.32% had Non-Q MI and 4.88% needed target vessel revascularization again.

Conclusion: Single-bolus eptifibatide is a safe and highly cost-effective alternative to conventional regimens.

How to Cite: Ahsan SA, Salim MA, Rafiq A, Siddique A, Banerjee SK, Haque H, et al.. Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary intervention (PCI) in a tertiary level hospital in Bangladesh. Global Heart. 2011;6(3):67–70. DOI: http://doi.org/10.1016/j.cvdpc.2011.04.001
1
Views
2
Downloads
Published on 01 Sep 2011.

Downloads

  • PDF (EN)

    comments powered by Disqus